Live Breaking News & Updates on Ulcerative colitis development program to takeda

Finch Therapeutics Reports Fourth Quarter and Full Year

SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

Marc-blaustein , Mark-smith , Greg-perry , American-college-of-gastroenterology , Finch-therapeutics-group-inc , Ulcerative-colitis-development-program-to-takeda , Clinical-development , Therapeutics-group , Human-first-discovery , Chief-executive-officer , Chief-financial-officer , Chief-operating-officer